viewCircassia Group PLC

Circassia Pharmaceuticals hails “major strategic milestone” with COPD product launch

Duaklir is a long-acting treatment that comes in powder form and is administered using an inhaler

Circassia Pharmaceuticals PLC -

Respiratory specialist Circassia Pharmaceuticals PLC (LON:CIR) will later Monday announce the US launch of a new product for chronic obstructive pulmonary disease (COPD), describing the landmark as a “major strategic milestone”.

It is using the American College of Chest Physicians' CHEST Annual Meeting in New Orleans as the springboard for Duaklir, which will be sold alongside Tudorza by a dedicated COPD workforce.

Duaklir is a long-acting treatment that comes in powder form and is administered using an inhaler.

The medication is a LAMA/LABA formulation, meaning it uses the muscarinic antagonist, aclidinium bromide, and the beta agonist, formoterol fumarate.

The market for these combination treatments is growing strongly in the States.

"The US launch of Duaklir represents a major strategic milestone for Circassia, significantly boosting our portfolio of marketed respiratory products and strengthening our offering of COPD treatments alongside our aclidinium monotherapy, Tudorz,” said Steve Harris chief executive, Steve Harris.

COPD is a progressive and life-threatening lung disease, which affects around 11mln Americans.

Circassia is a specialty pharma company focused on treating patients with respiratory diseases.

It has two other products on the market: NIOX, which is used to help manage asthma, and the aforementioned Tudorza.

Tudorza and Duaklir have both been in-licensed from FTSE 100 giant AstraZeneca PLC (LON:AZN).

It has several other asthma and COPD treatments in its pipeline, as well as AirNOvent – a portable system that uses electricity to make nitric oxide which is used to dilate blood vessels in the lungs.

Quick facts: Circassia Group PLC

Price: 23.36 GBX

Market: LSE
Market Cap: £87.76 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Circassia Group PLC named herein, including the promotion by the Company of Circassia Group PLC in any Content on the Site, the Company...



Full interview: Circassia Pharmaceuticals' commercial development...

Circassia Pharmaceuticals PLC's (LON:CIR) CEO Steve Harris tells Proactive London's Andrew Scott they saw strong growth in the first half of the year alongside a reduction in costs and cash outflows. Revenues for the six months ended June 30 were up 40% year-on-year at £27.9mln, with the...

on 26/9/19

2 min read